NASDAQ:PCRX - Pacira Biosciences Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Pacira Biosciences Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $33.49 -0.04 (-0.12 %) (As of 04/1/2020 11:32 AM ET) Add Compare Today's Range$32.55Now: $33.49▼$33.9150-Day Range$28.40MA: $40.54▼$50.7052-Week Range$27.46Now: $33.49▼$51.35Volume9,659 shsAverage Volume999,085 shsMarket Capitalization$1.41 billionP/E RatioN/ADividend YieldN/ABeta1.15 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for health care practitioners and their patients in the United States. The company develops products based on its proprietary DepoFoam product delivery technology that encapsulates drugs without altering their molecular structure. It offers EXPAREL, a non-opioid medication administered at the time of surgery to control pain while reducing opioid requirements; and iovera system, a handheld cryoanalgesia device used to deliver controlled doses of cold temperature only to targeted nerves. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was founded in 2006 and is based in Parsippany, New Jersey.Read More Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals SectorMedical Current SymbolNASDAQ:PCRX Previous Symbol CUSIP69512710 CIK1396814 Webhttp://www.pacira.com/ Phone973-254-3560Debt Debt-to-Equity Ratio0.98 Current Ratio3.79 Quick Ratio3.25Price-To-Earnings Trailing P/E RatioN/A Forward P/E Ratio45.88 P/E Growth1.41 Sales & Book Value Annual Sales$421.03 million Price / Sales3.34 Cash Flow$1.72 per share Price / Cash Flow19.52 Book Value$8.51 per share Price / Book3.94Profitability EPS (Most Recent Fiscal Year)$0.86 Net Income$-11,020,000.00 Net Margins-2.62% Return on Equity10.81% Return on Assets4.71%Miscellaneous Employees518 Outstanding Shares42,030,000Market Cap$1.41 billion Next Earnings Date5/7/2020 (Estimated) OptionableOptionable Receive PCRX News and Ratings via Email Sign-up to receive the latest news and ratings for PCRX and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:PCRX Rates by TradingView Pacira Biosciences (NASDAQ:PCRX) Frequently Asked Questions How has Pacira Biosciences' stock been impacted by COVID-19 (Coronavirus)? Pacira Biosciences' stock was trading at $35.19 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, PCRX stock has decreased by 4.8% and is now trading at $33.49. View which stocks have been mosted impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Pacira Biosciences? 15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pacira Biosciences in the last year. There are currently 4 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Pacira Biosciences. When is Pacira Biosciences' next earnings date? Pacira Biosciences is scheduled to release its next quarterly earnings announcement on Thursday, May 7th 2020. View our earnings forecast for Pacira Biosciences. How were Pacira Biosciences' earnings last quarter? Pacira Biosciences Inc (NASDAQ:PCRX) announced its quarterly earnings results on Thursday, February, 20th. The company reported $0.56 EPS for the quarter, beating the consensus estimate of $0.21 by $0.35. The firm had revenue of $122.42 million for the quarter, compared to analyst estimates of $122.04 million. Pacira Biosciences had a positive return on equity of 10.81% and a negative net margin of 2.62%. The firm's revenue was up 28.7% on a year-over-year basis. During the same period in the previous year, the company earned $0.47 EPS. View Pacira Biosciences' earnings history. What guidance has Pacira Biosciences issued on next quarter's earnings? Pacira Biosciences updated its FY 2020 Pre-Market earnings guidance on Thursday, February, 20th. The company provided EPS guidance of for the period. The company issued revenue guidance of $485-500 million, compared to the consensus revenue estimate of $495.91 million. What price target have analysts set for PCRX? 15 analysts have issued 12 month price objectives for Pacira Biosciences' shares. Their forecasts range from $38.00 to $85.00. On average, they expect Pacira Biosciences' share price to reach $54.00 in the next year. This suggests a possible upside of 61.2% from the stock's current price. View analysts' price targets for Pacira Biosciences. What are Wall Street analysts saying about Pacira Biosciences stock? Here are some recent quotes from research analysts about Pacira Biosciences stock: 1. According to Zacks Investment Research, "Pacira changed its name to Pacira BioSciences after acquiring MyoScience in April 2019 following which, it added the latter’s iovera system to its portfolio.. Pacira's top line mainly comprises contribution from its marketed drug Exparel, which continues to maintain momentum. The drug’s label expansion to include administration via nerve block for prolonged regional analgesia is expected to further boost sales in the days ahead. Pacira’s agreement with Nuance for the development and commercialization of Exparel in China is a tailwind. The company's shares have outperformed the industry in the past year. However, Pacira remains heavily dependent on Exparel for growth. Therefore, any regulatory setback for the drug will severely hurt the stock." (3/27/2020) 2. Stifel Nicolaus analysts commented, "We are upgrading shares of PCRX to Hold as we believe the near-term competitive threat from HRTX’s HTX-011 will be less of a factor over the next 12 months and the recent strength in the stock indicates to us that the stock is fairly valued at these levels. While PCRX’s Exparel revenues came in a little shy of 1Q19 consensus, we believe the recent price increase on Exparel, the lack of a competitive entry from HRTX and the favorable reimbursement scheme in the ASC setting should allow PCRX to achieve its 2019 Exparel guidance, in our view. Our revised 2019 Exparel estimates are now at the midpoint of management’s guidance of ~$400-$410 million (vs. consensus of ~$403 million). Additionally, we incorporate PCRX’s recent acquisition, Iovera, into our model and raise our target price to $45 a share." (5/2/2019) Has Pacira Biosciences been receiving favorable news coverage? News stories about PCRX stock have been trending very negative this week, InfoTrie Sentiment reports. The research group scores the sentiment of media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Pacira Biosciences earned a coverage optimism score of -3.0 on InfoTrie's scale. They also gave news stories about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the near term. View the latest news aboutPacira Biosciences. Who are some of Pacira Biosciences' key competitors? Some companies that are related to Pacira Biosciences include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), AbbVie (ABBV), Allergan (AGN), Zoetis (ZTS), Mylan (MYL), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Horizon Therapeutics (HZNP), Nektar Therapeutics (NKTR), Corcept Therapeutics (CORT) and Zogenix (ZGNX). What other stocks do shareholders of Pacira Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Pacira Biosciences investors own include Gilead Sciences (GILD), ACADIA Pharmaceuticals (ACAD), Celgene (CELG), Clovis Oncology (CLVS), NVIDIA (NVDA), Micron Technology (MU), Alibaba Group (BABA), Bausch Health Companies (BHC), Exelixis (EXEL) and Incyte (INCY). Who are Pacira Biosciences' key executives? Pacira Biosciences' management team includes the following people: Mr. David M. Stack, Chairman & CEO (Age 69)Mr. Charles A. Reinhart III, CPA, M.B.A., Chief Financial Officer (Age 58)Ms. Kristen Williams, Chief Admin. Officer & Sec. (Age 45)Dr. Richard Scranton M.D., MPH, Chief Medical Officer (Age 52)Mr. Dennis McLoughlin, Chief Commercial Officer (Age 53) What is Pacira Biosciences' stock symbol? Pacira Biosciences trades on the NASDAQ under the ticker symbol "PCRX." How do I buy shares of Pacira Biosciences? Shares of PCRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Pacira Biosciences' stock price today? One share of PCRX stock can currently be purchased for approximately $33.49. How big of a company is Pacira Biosciences? Pacira Biosciences has a market capitalization of $1.41 billion and generates $421.03 million in revenue each year. The company earns $-11,020,000.00 in net income (profit) each year or $0.86 on an earnings per share basis. Pacira Biosciences employs 518 workers across the globe. View additional information about Pacira Biosciences. What is Pacira Biosciences' official website? The official website for Pacira Biosciences is http://www.pacira.com/. How can I contact Pacira Biosciences? Pacira Biosciences' mailing address is 5 SYLVAN WAY SUITE 300, PARSIPPANY NJ, 07054. The company can be reached via phone at 973-254-3560 or via email at [email protected] MarketBeat Community Rating for Pacira Biosciences (NASDAQ PCRX)Community Ranking: 2.9 out of 5 ( )Outperform Votes: 724 (Vote Outperform)Underperform Votes: 546 (Vote Underperform)Total Votes: 1,270MarketBeat's community ratings are surveys of what our community members think about Pacira Biosciences and other stocks. Vote "Outperform" if you believe PCRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PCRX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 4/1/2020 by MarketBeat.com StaffFeatured Article: Quiet Period Expirations Explained
